A CME Symposium during the 2026 Annual Meeting for the American Association of Heart Failure Nurses in San Diego, California.

AGENDA
 

10:30 AM           Introduction

                          Lisa Rathman, MSN, CRNP, ACNP-BC, CHFN

10:33 AM           MRAs in HF: The Changing Landscape

                           Ankeet Bhatt, MD, MBA, ScM

10:55 AM           Case Presentation: Best Practices for Using Foundational Therapies and Key Messages for Patients

                           Lisa Rathman, MSN, CRNP, ACNP-BC, CHFN

11:10 AM            Question and Answer

EDUCATIONAL OBJECTIVES

1. Describe the clinical data for steroidal mineralocorticoid receptor antagonists (sMRAs) through the spectrum of ejection fraction in heart failure and their safety profiles and tolerability.

2. Explain the pharmacologic profi le/characteristics of nonsteroidal MRA (nsMRA) therapy and clinical evidence in patients with heart failure with mildly reduced ejection fraction (HFmrEF) and heart failure with preserved ejection fraction (HFpEF).

3. Summarize information for initiation of evidence-based therapies in HFmrEF and HFpEF patients and prudent follow-up.

Educational Grant

This activity is supported by an independent educational grant from Bayer.

CHAIR

Lisa Rathman, MSN, CRNP, ACNP-BC, CHFN

Lead Nurse Practitioner Heart Failure Section

Penn Medicine Lancaster General Health

Lancaster, Pennsylvania

Ankeet S. Bhatt, MD, MBA, ScM

Assistant Professor

Kaiser Permanente Bernard J. Tyson School of Medicine

Pasadena, California

A CME Symposium during the 2026 Annual Meeting for the American Association of Heart Failure Nurses in San Diego, California.

AGENDA

3:50 pm           Introduction

                        Margaret Cuomo, NP (Chair)

3:53 pm           When Should I Think About Transthyretin Cardiac Amyloidosis

                        Margaret Cuomo, NP

4:08 pm           Diagnosis of ATTR-CM and Treatment with Disease-Modifying Therapies

                        Justin Grodin, MD, MPH

4:28 pm           ATTR-CM in HF: Questions and Answers for Real-World Practice

                        Margaret Cuomo, NP and Justin Grodin, MD, MPH

4:40 pm           Question and Answer

EDUCATIONAL OBJECTIVES

• Indicate red flags which raise suspicion for ATTR-CM and identify specific patient populations where the disease is prevalent

• Recognize the criteria for diagnosing ATTR-CM and interpret the evidence with disease-modifying therapies

• Discuss best use of HF GDMT in individuals with ATTR-CM

• Describe recommended monitoring of disease progression and summarize roles for HF nurses in overall management of ATTR-CM

Educational Grant

This program is supported by an independent educational grant provided by Alnylam.

CHAIR

Margaret Cuomo, NP

Columbia University Irving Medical Center

New York, New York

FACULTY

Justin Grodin, MD, MPH

Associate Professor of Medicine

Department of Internal Medicine – Division of Cardiology

University of Texas Southwestern Medical Center

Dallas, Texas